These results are consistent with our previous report showing the combination treatment of ganetespib and lapatinib enhances RTK signaling inhibition in gastric cancer cells28, which further indicate the potential application of ganetespib + lapatinib as a synergistic combinational therapy for ErbB2+ breast cancer. Here, ERBB2 is linked to breast carcinoma.